Autor segons l'article: Cordero, A; González-Gallarza, RD; Masana, L; Fuster, V; Castellano, JM; Olivar, JER; Zsolt, I; Sicras-Mainar, A; Juanatey, JRG
Departament: Medicina i Cirurgia
Autor/s de la URV: Masana Marín, Luis
Paraules clau: Use of healthcare resources Strategy Spain Secondary prevention Risk Healthcare costs Health Global burden Fixed-dose combination European-society Epidemiology Dyslipidemia Disease Cnic-polypill Cardiovascular events Adherence
Resum: Purpose: The aim of this study was to estimate health-care resources utilization, costs and cost-effectiveness associated with the treatment with CNIC-Polypill as secondary prevention of atherosclerotic cardiovascular disease (ASCVD) compared to other treatments, in clinical practice in Spain.Patients and Methods: An observational, retrospective study was performed using medical records (economic results [health-care perspective], NEPTUNO-study; BIG-PAC-database) of patients who initiated secondary prevention between 2015 and 2018. Patients were followed up to 2 years (maximum). Four cohorts were balanced with a propensity-score-matching (PSM): 1) CNIC-Polypill (aspirin+atorvastatin+ramipril), 2) Monocomponents (same separate drugs), 3) Equipotent (equipotent drugs) and 4) Other therapies ([OT], other cardiovascular drugs). Incidence of cardiovascular events, health-care resources utilization and healthcare and non-healthcare costs (2020 Euros) were compared. Incremental cost-effectiveness ratios per cardiovascular event avoided were estimated.Results: After PSM, 1614 patients were recruited in each study cohort. The accumulated incidence of cardiovascular events during the 24-month follow-up was lower in the CNIC-Polypill cohort vs the other cohorts (19.8% vs Monocomponents: 23.3%, Equipotent: 25.5% and OT: 26.8%; p<0.01). During the follow-up period, the CNIC-Polypill cohort also reduced the health-care resources utilization per patient compared to the other cohorts, particularly primary care visits (16.6 vs Monocomponents: 18.7, Equipotent: 18.9 and OT: 21.0; p<0.001) and hospitalization days (2.3 vs Monocomponents: 3.4, Equipotent: 3.7 and OT: 4.0; p<0.001). The treatment cost in the CNIC-Polypill cohort was lower than that in the other cohorts (euro4668 vs Monocomponents: euro5587; Equipotent: euro5682 and OT: euro6016; p<0.001) (Difference:-euro919,-euro1014 and-euro1348, respectively). Due to the reduction of cardiovascular events and costs, the CNIC-Polypill is a dominant alternative compared to the other treatments.Conclusion: CNIC-Polypill reduces recurrent major cardiovascular events and costs, being a cost-saving strategy as secondary prevention of ASCVD.
Àrees temàtiques: Interdisciplinar Health policy Health care sciences & services Economics, econometrics and finance (miscellaneous) Ciencias sociales
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: luis.masana@urv.cat
Identificador de l'autor: 0000-0002-0789-4954
Data d'alta del registre: 2024-08-03
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
Enllaç font original: https://www.dovepress.com/economic-burden-associated-with-the-treatment-with-a-cardiovascular-po-peer-reviewed-fulltext-article-CEOR
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Clinicoeconomics And Outcomes Research. 15 559-571
Referència de l'ítem segons les normes APA: Cordero, A; González-Gallarza, RD; Masana, L; Fuster, V; Castellano, JM; Olivar, JER; Zsolt, I; Sicras-Mainar, A; Juanatey, JRG (2023). Economic Burden Associated with the Treatment with a Cardiovascular Polypill in Secondary Prevention in Spain: Cost-Effectiveness Results of the NEPTUNO Study. Clinicoeconomics And Outcomes Research, 15(), 559-571. DOI: 10.2147/CEOR.S396290
DOI de l'article: 10.2147/CEOR.S396290
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2023
Tipus de publicació: Journal Publications
Repositori URV